AZN Share PerformanceMore
|52 week high||5,520 22/06/17|
|52 week low||4,137 27/01/17|
|52 week change||431 (9.41%)|
|4 week volume||36,623,396 22/12/17|
Latest News« previous» nextMore
16/01/2018 - 13:40 StockMarketWire
Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and set its price target ...
16/01/2018 - 10:50 StockMarketWire
Exane BNP Paribas today reaffirms its outperform investment rating on AstraZeneca PLC (LON:AZN) and set its price ta...
12/01/2018 - 16:10 RNS
RNS Number: 7898B AstraZeneca PLC 12 January 2018 12 January 2018 16:10 GMT LYNPARZA APPROVED BY US FDA IN GERMLINE BRCA -MUTATED METASTATIC BREAST CANCER Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Lynparza reduced the risk of disease progression or death by 42% compared to sta...
12/01/2018 - 10:11 Interactive Investor
Leading market commentator David Buik tells Interactive Investor who he thinks the winners will be this year and where...
11/01/2018 - 10:30 StockMarketWire
Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and set its price target at 5700p...
10/01/2018 - 15:10 RNS
RNS Number: 5204B AstraZeneca PLC 10 January 2018 10 January 2018 15:10 GMT FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA Approval based on Phase III WINDWARD programme that demonstrated significant reductions in asthma exacerbations, improvements in lung function and reductions in oral corticosteroid use from...
02/01/2018 - 15:00 RNS
RNS Number: 7321A AstraZeneca PLC 02 January 2018 2 January 2018 15:00 GMT Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 December 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,266,221,605...
28/12/2017 - 14:00 RNS
RNS Number: 4358A AstraZeneca PLC 28 December 2017 28 December 2017 14:00 GMT TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES - AMENDMENT Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements...
Latest discussion posts More
“The US Food and Drug Administration has accepted AstraZeneca's regulatory submission for Tagrisso for the treatment of patients with metastatic non-small cell lung cancer. ...”▼
“AstraZeneca has submitted a supplemental new drug application for its lung cancer drug Tagrisso to Japan's Pharmaceuticals and Medical Devices Agency. AstraZenecahas submitted ...”▼
“"When Equilibrium's Mike Deverell built our Long-Term Growth portfolio in the spring, he was cautious about the stockmarket. Holly Black reports on what's changed since.With ...”▼
Codes & Symbols
|Symbols||AZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment